Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05267522
Other study ID # 204327
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date August 31, 2023

Study information

Verified date March 2022
Source University of South Australia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will comprise a randomized controlled, counter-balanced, cross-over trial to evaluate the independent effects of a high cholesterol (high egg), low saturated fat diet and a high saturated fat, low cholesterol diet on blood lipids. Evaluations also include analysis of physical activity as there is emerging evidence that the lutein and zeaxanthin in egg yolk may increase physical activity levels by crossing the blood-brain barrier and altering neuronal function. The study will also investigate effects on a number of novel lipoprotein parameters (particle size and particle concentrations).


Description:

Eggs are high in cholesterol but low in saturated fat. Data from cross-sectional, prospective, and randomized controlled trials (RCTs), suggest that egg intake does not adversely affect blood lipids or increase cardiovascular disease (CVD) risk. In fact, there is some evidence that egg consumption may reduce CVD risk. However, to date there has been no direct comparison of the effects of a high cholesterol (high egg), low saturated fat diet and a low cholesterol, high-saturated fat diet on blood lipids, and no studies have accounted for potential effects of differences in physical activity, which can also influence the blood lipid profile. Evaluations of the effect of egg consumption on blood lipids should include analysis of physical activity as there is emerging evidence that the lutein and zeaxanthin in egg yolk may increase physical activity levels by crossing the blood-brain barrier and altering neuronal function. We will directly compare the effects of a high cholesterol, low saturated fat diet and a low cholesterol, high saturated fat diet on blood lipids, using egg consumption to manipulate dietary cholesterol intake, while also accounting for physical activity levels. The study will investigate effects on a number of novel lipoprotein parameters (particle size and particle concentrations).


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date August 31, 2023
Est. primary completion date August 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Male or female, aged 18 - 60 years - Blood LDL-C <3.5 mmol/L (measured at screening using an automated analyser (Cholestech LDX System). - Non-smoker (or other nicotine products) (minimum 6 months). Exclusion Criteria: - Have diagnosed cardiovascular disease (including uncontrolled high blood pressure) or a chronic disease, including Type-1 or -2 diabetes, kidney or liver disease, gastrointestinal disorders requiring medical nutrition therapy (e.g., Crohn's disease, irritable bowel, coeliac disease) or any other condition that may have an impact on study outcomes. - Have allergies or strong aversion to eggs or other components of the test foods (diets are not suitable for vegetarians). - Consume more than 5 eggs per week in the month prior to beginning the trial. - Participant has a recent history (within 12 months) or strong potential for alcohol abuse. Defined as >14 standard drinks per week. - Have changed medication or supplementation that might affect study outcomes in the last 3 months. - Take vitamin, mineral, herbal supplementation, or medications that may have an impact on study outcomes. - Are already involved in another research project within 30 days of commencement of the present study that in the opinion of the investigators will be unsuitable for this study. - Are pregnant or breastfeeding. - Show unwillingness to be randomized to either experimental group. - Failure to satisfy the investigator regarding suitability to participate for any other reason. - Are unwilling or unable to provide written informed consent.

Study Design


Intervention

Other:
Egg diet
30% fat [6% saturated fat], 20% protein, 40% carbohydrate, 600 mg cholesterol
Egg-free Diet
30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 300 mg cholesterol
Control Diet
30% fat [12% saturated fat], 25% protein, 40% carbohydrate, 600 mg cholesterol

Locations

Country Name City State
Australia University of South Australia Clinical Trial Facility Adelaide South Australia

Sponsors (2)

Lead Sponsor Collaborator
University of South Australia American Egg Board

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Low-density lipoprotein cholesterol (LDL-C) Plasma LDL-C levels (mmol/L) Baseline
Primary Low-density lipoprotein cholesterol (LDL-C) Plasma LDL-C levels (mmol/L) 5 weeks
Primary Low-density lipoprotein cholesterol (LDL-C) Plasma LDL-C levels (mmol/L) 10 weeks
Primary Low-density lipoprotein cholesterol (LDL-C) Plasma LDL-C levels (mmol/L) 15 weeks
Secondary Blood lipid profiling Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins Baseline
Secondary Blood lipid profiling Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins 5 weeks
Secondary Blood lipid profiling Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins 10 weeks
Secondary Blood lipid profiling Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins 15 weeks
Secondary Fasting glucose Plasma glucose levels (mmol/L) Baseline
Secondary Fasting glucose Plasma glucose levels (mmol/L) 5 weeks
Secondary Fasting glucose Plasma glucose levels (mmol/L) 10 weeks
Secondary Fasting glucose Plasma glucose levels (mmol/L) 15 weeks
Secondary Physical activity levels Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity Baseline
Secondary Physical activity levels Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity 5 weeks
Secondary Physical activity levels Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity 10 weeks
Secondary Physical activity levels Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity 15 weeks
Secondary Waist circumference Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. Baseline
Secondary Waist circumference Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. 5 weeks
Secondary Waist circumference Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. 10 weeks
Secondary Waist circumference Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. 15 weeks
Secondary Blood Pressure Seated blood pressure (mmHg) Baseline
Secondary Blood Pressure Seated blood pressure (mmHg) 5 weeks
Secondary Blood Pressure Seated blood pressure (mmHg) 10 weeks
Secondary Blood Pressure Seated blood pressure (mmHg) 15 weeks
Secondary Dietary saturated fat intake Analysis of dietary intake based on 5-day food diaries Baseline
Secondary Dietary saturated fat intake Analysis of dietary intake based on 5-day food diaries 5 weeks
Secondary Dietary saturated fat intake Analysis of dietary intake based on 5-day food diaries 10 weeks
Secondary Dietary saturated fat intake Analysis of dietary intake based on 5-day food diaries 15 weeks
Secondary Dietary cholesterol intake Analysis of dietary intake based on 5-day food diaries Baseline
Secondary Dietary cholesterol intake Analysis of dietary intake based on 5-day food diaries 5 weeks
Secondary Dietary cholesterol intake Analysis of dietary intake based on 5-day food diaries 10 weeks
Secondary Dietary cholesterol intake Analysis of dietary intake based on 5-day food diaries 15 weeks
Secondary Dietary Energy intake Analysis of dietary intake based on 5-day food diaries Baseline
Secondary Dietary Energy intake Analysis of dietary intake based on 5-day food diaries 5 weeks
Secondary Dietary Energy intake Analysis of dietary intake based on 5-day food diaries 10 weeks
Secondary Dietary Energy intake Analysis of dietary intake based on 5-day food diaries 15 weeks
Secondary Dietary Macronutrients Analysis of dietary intake based on food diaries Baseline
Secondary Dietary Macronutrients Analysis of dietary intake based on food diaries 5 weeks
Secondary Dietary Macronutrients Analysis of dietary intake based on food diaries 10 weeks
Secondary Dietary Macronutrients Analysis of dietary intake based on food diaries 15 weeks
Secondary Dietary Lutein+Zeaxanthin Analysis of dietary intake based on food diaries Baseline
Secondary Dietary Lutein+Zeaxanthin Analysis of dietary intake based on food diaries 5 weeks
Secondary Dietary Lutein+Zeaxanthin Analysis of dietary intake based on food diaries 10 weeks
Secondary Dietary Lutein+Zeaxanthin Analysis of dietary intake based on food diaries 15 weeks
Secondary Sleep Sleep patterns assessed using accelerometers Baseline
Secondary Sleep Sleep patterns assessed using accelerometers 5 weeks
Secondary Sleep Sleep patterns assessed using accelerometers 10 weeks
Secondary Sleep Sleep patterns assessed using accelerometers 15 weeks
See also
  Status Clinical Trial Phase
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Recruiting NCT03947866 - Ezetimibe-Rosuvastatin Evaluation Study
Completed NCT01709513 - Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) Phase 3
Completed NCT01212900 - Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression Phase 4
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02550288 - A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383) Phase 3
Completed NCT03929198 - Translation of Pritikin Program to the Community N/A
Completed NCT04485793 - Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia N/A
Completed NCT02341924 - Validating the "Foods for Health" Portfolio of Functional Food Products N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT01941836 - Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients Phase 2
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01670734 - Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects Phase 1
Completed NCT01678521 - Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients N/A
Completed NCT01370590 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Phase 3
Completed NCT01370603 - A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1) Phase 3
Completed NCT01768403 - Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia N/A
Completed NCT01446679 - Special Drug Use-Results Survey of Lipitor Tablets N/A
Completed NCT01575171 - Using Nudges to Implement Comparative Effectiveness N/A